The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction

Aims/hypothesis. Although retinoid X receptor (RXR) and peroxisome prolifer ator activated receptor-gamma (PPAR gamma) agonists have antidiabetic effec ts in hyperinsulinaemic animals, little information exists on their effects after pancreatic beta-cell failure. Thus, we examined if RXR and PPAR gamm a agonists alter distinct metabolic pathways in animals suffering from impa ired insulin secretion. Methods. Adverse side effects and antidiabetic responses were measured in d b/db mice treated from 14-16 weeks of age with the RXR agonist, LG100268, a nd/or the PPAR gamma agonists, BRL49653 or GW1929. Results. In animals trea ted with LG100268 or BRL49653, serum glucose, glycohaemoglobin and the card iovascular risk factor, fibrinogen, decreased to the same extent. Both of t hese agonists were equally effective at increasing insulin accumulation in beta cells, although neither agent had an effect on serum insulin concentra tions. In contrast, the RXR agonist was less effective than the PPAR gamma agonists at lowering serum triglycerides and non-esterified fatty acids and increasing interscapular brown fat and body weight. Further, LG100268 incr eased serum alkaline phosphatase and liver mass, hepatic fat accumulation, lauric acid hydroxylase activity, catalase-immunostaining and peroxisomal n umber more than the PPAR gamma agonists. Moreover, co-treatment with the RX R and PPAR gamma agonists reduced glucose, triglycerides, non-esterified fa tty acids and cholesterol more than either agent alone. Conclusion/interpretation. These data suggest 1) RXR and PPAR gamma agonist s decrease islet degeneration, cardiovascular risk and cachexia during late r stages of diabetes, 2) RXR agonists are less effective than PPAR gamma ag onists at decreasing serum lipids and causing weight gain and 3) RXR agonis ts have a more pronounced effect on liver metabolism (e.g. peroxisome accum ulation and hepatomegaly) than PPAR gamma agonists.